Toronto Dominion Bank Raises Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Toronto Dominion Bank lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 4.2% in the 3rd quarter, Holdings Channel reports. The firm owned 25,622 shares of the company’s stock after acquiring an additional 1,022 shares during the period. Toronto Dominion Bank’s holdings in Apellis Pharmaceuticals were worth $739,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Braidwell LP increased its holdings in Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after buying an additional 2,513,383 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Apellis Pharmaceuticals by 191.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after acquiring an additional 1,409,707 shares during the period. Fiera Capital Corp grew its stake in shares of Apellis Pharmaceuticals by 47.7% in the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after acquiring an additional 452,753 shares during the period. Sphera Funds Management LTD. purchased a new position in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $6,226,000. Finally, AQR Capital Management LLC lifted its position in Apellis Pharmaceuticals by 337.3% during the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after purchasing an additional 190,420 shares during the period. 96.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on APLS shares. Citigroup cut their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group lowered their target price on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company dropped their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, William Blair began coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set an “outperform” rating for the company. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $49.94.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $33.66 on Tuesday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $73.80. The stock’s 50-day simple moving average is $29.78 and its 200-day simple moving average is $34.67. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -16.58 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.17) earnings per share. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).